<DOC>
	<DOC>NCT01018758</DOC>
	<brief_summary>This is an open-label, multicenter phase II study in patients with aggressive Non Hodgkin Lymphoma scheduled to receive moderately emetogenic polychemotherapy (according to modified Hesketh classification for antiemetic therapy).</brief_summary>
	<brief_title>Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Palonosetron</mesh_term>
	<mesh_term>Emetics</mesh_term>
	<criteria>Male or female, &gt;18 years of age; Histologically or cytologically confirmed aggressive NHL (any stage in accordance with the REAL Classification); Patients candidates to a initial chemotherapy treatment; ECOG performance status of 01; Scheduled to receive a single intravenous dose of at least one of the moderately emetogenic agents (according to the modified Hesketh classification) on Day 1; Written informed consent; Female of childbearing potential must be using reliable contraceptive measures; Acceptable hepatic and renal functions; Willing and able to complete the patient diary. Highly emetogenic chemotherapy (containing cisplatin, mechlorethamine, streptozotocin, cyclophosphamide &gt;1500 mg/sqm; carmustine; dacarbazine; hexamethylmelamine; procarbazine), or singleagent chemotherapy with drugs having low/minimal emetogenic potential according to the Hesketh classification); Diagnosis of Hodgkin's Disease or Leukemia; Candidates to HighDose Chemotherapy or Bone Marrow/Peripheral Blood Stem Cells Transplantation; Chemotherapy schedules considering the administration of emetogenic drugs in more than two consecutive days; Have received any investigational drugs within 30 days before study entry; Have received any drug with potential antiemetic efficacy (with the exception of specific corticosteroids foreseen in the chemotherapy combination) within 24 hours of treatment initiation); Prior treatment with Palonosetron; Have a seizure disorder requiring anticonvulsant medication unless clinically stable and free of seizure activity; Experienced or ongoing vomiting or nausea from any organic etiology, in the screening phase; Clinical evidence of current or impending bowel obstruction, peritonitis, infection, uremia, severe mucositis; Clinically relevant electrolyte abnormalities; Have a known hypersensitivity to 5HT3 receptor antagonists; Radiotherapy within 30 days before chemotherapy administration, or scheduled to receive radiotherapy within two weeks after chemotherapy; Female patients who are pregnant or breast feeding; Inability to understand or cooperate with the study procedures.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Non-Hodgkin's lymphoma</keyword>
	<keyword>Quality of life</keyword>
	<keyword>Chemotherapy toxicity</keyword>
	<keyword>aggressive Non Hodgkin's Lymphomas treated with moderately emetogenic chemotherapy</keyword>
</DOC>